Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). Wave claims this is the first clinical ...
U.S. 3 Year Treasury Note-0.051 3.641% U.S. 5 Year Treasury Note-0.060 3.771% U.S. 7 Year Treasury Note-0.091 3.964% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results